Defunct Company
Total Trials
3
As Lead Sponsor
As Collaborator
0
Total Enrollment
174
NCT04718675
A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)
Phase: Phase 1/2
Role: Lead Sponsor
Start: Feb 8, 2021
Completion: Feb 7, 2025
NCT05020665
Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML
Phase: Phase 3
Start: Nov 24, 2021
Completion: Mar 30, 2023
NCT05028751
A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)
Start: Aug 5, 2022
Completion: Apr 9, 2024